Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Plantago Major
Generic Name
Plantago Major
Active Ingredient
Plantago MajorCategory
Nitrogen Binding Agent [EPC]
Variants
10
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 100 [hp_C]/1 | PELLET | ORAL | 37662-1360 |
| 200 [kp_C]/200[kp_C] | PELLET | ORAL | 0220-4088 |
| 30 [hp_C]/1 | PELLET | ORAL | 37662-1359 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Plantago Major, you must consult a qualified healthcare professional.
| 30 [hp_C]/30[hp_C] | PELLET | ORAL | 0220-4087 |
| 6 [hp_C]/6[hp_C] | PELLET | ORAL | 0220-4086 |
| 200 [hp_C]/1 | PELLET | ORAL | 37662-1361 |
| 500 [hp_C]/1 | PELLET | ORAL | 37662-1362 |
| 6 [hp_C]/1 | PELLET | ORAL | 37662-1357 |
| 12 [hp_C]/1 | PELLET | ORAL | 37662-1358 |
| 1 [hp_M]/1 | PELLET | ORAL | 37662-1363 |
Detailed information about Plantago Major
Plantago Major is a multi-faceted therapeutic agent primarily classified as a Nitrogen Binding Agent [EPC]. It is used in allergenic extracts and investigated for its ammonium ion binding activity in metabolic management.
The dosage of Plantago Major varies significantly based on the intended therapeutic use and the specific formulation being administered.
In adults, the typical oral dosage of concentrated Plantago Major extract ranges from 500 mg to 1,500 mg daily, usually divided into two or three doses. Healthcare providers often start at the lower end of the spectrum to assess gastrointestinal tolerance before titrating upward. For maximum ammonium binding efficiency, doses are frequently administered shortly after meals when nitrogenous waste production is highest.
When used as an allergenic extract, the dosage is highly individualized and follows a "build-up" phase followed by a "maintenance" phase.
Plantago Major extracts have been used in pediatric populations, particularly for allergy immunotherapy, but must be managed with extreme caution by a specialist.
In patients with compromised kidney function (CrCl < 60 mL/min), the excretion of absorbed Plantago Major metabolites may be delayed. While the primary nitrogen-binding action occurs in the gut, systemic accumulation of active glycosides could occur. Healthcare providers may reduce the frequency of dosing or the total daily amount by 25-50% in patients with Stage 3 or higher chronic kidney disease.
Since the liver is the primary site for the metabolism of Plantago Major’s active glycosides, patients with hepatic insufficiency (Child-Pugh Class B or C) require careful monitoring. Dose adjustments are generally not required for the nitrogen-binding effect, but the systemic immunomodulatory effects may be prolonged.
Geriatric patients often have reduced renal clearance and a higher prevalence of polypharmacy. Dosing should start at the lowest possible range. Monitoring for dehydration and electrolyte balance is essential, as the mucilage content can affect fluid absorption in the gut.
If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double the dose to make up for a missed one, as this increases the risk of gastrointestinal obstruction or metabolic imbalance.
Signs of an acute overdose of Plantago Major may include:
In the event of a suspected overdose, contact a poison control center immediately or seek emergency medical attention. Treatment is generally supportive, focusing on hydration and electrolyte replacement.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Regular follow-up appointments are necessary to monitor the efficacy of the treatment.
Most patients taking Plantago Major for nitrogen binding or as part of an allergenic extract regimen experience mild side effects. The most common involve the gastrointestinal tract and the site of administration.
Plantago Major is a potent pharmacological agent that requires careful clinical oversight. It is not a simple herbal supplement when used in standardized concentrations for nitrogen binding or immunotherapy. Patients must be aware that the "natural" origin of the drug does not preclude it from causing significant systemic effects or interacting with other medications. It is vital to maintain adequate hydration while taking oral forms of Plantago Major to prevent gastrointestinal complications.
Severe Systemic Allergic Reactions: As noted in the side effects section, Plantago Major allergenic extracts carry an FDA-mandated warning regarding the potential for life-threatening anaphylaxis. This risk is highest during the build-up phase of immunotherapy or if a dose is significantly increased after a period of discontinuation. Patients must have access to an epinephrine auto-injector and be trained in its use.
Plantago Major must NEVER be used in the following circumstances:
Plantago Major is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been extensively performed for the standardized nitrogen-binding extracts.
It is not known whether the active glycosides or nitrogen-bound complexes of Plantago Major are excreted in human milk. Because many drugs are excreted in milk and the effects on a nursing infant’s developing immune system are unknown, caution should be exercised. If the mother requires Plantago Major for nitrogen regulation, the infant should be monitored for changes in bowel habits or allergic symptoms.
Plantago Major functions through a dual-action pharmacological pathway. Its primary clinical identity is as a Nitrogen Binding Agent [EPC]. The mechanism involves Ammonium Ion Binding Activity [MoA]. The active polysaccharides within the plant's cell walls contain carboxyl and hydroxyl groups that create a high-affinity environment for the ammonium ion (NH4+). In the alkaline environment of the small intestine, these groups ionize and trap nitrogenous waste products, preventing their conversion into urea or their re-entry into the portal circulation. This effectively lowers the systemic nitrogen load.
Additionally, Plantago Major acts as a Lymphocyte Growth Factor [EPC]. Research indicates that its water-soluble pectic polysaccharides can bind to receptors on the surface of T-cells, triggering a signaling cascade that involves the induction of Interferon gamma [EPC]. This enhances the cell-mediated immune response, which explains its role in wound healing and its complex behavior in allergenic extracts.
The dose-response relationship for Plantago Major is most evident in its nitrogen-binding capacity. Higher doses correlate with a greater reduction in fecal pH and a higher concentration of nitrogen in the stool. The onset of the nitrogen-binding effect occurs within 2-4 hours of oral administration, coinciding with the drug's transit into the lower gastrointestinal tract. The duration of effect lasts for approximately 8-12 hours per dose. Tolerance to the immunomodulatory effects has not been reported, but the body’s sensitivity to the allergenic components decreases over years of immunotherapy.
Common questions about Plantago Major
Plantago Major is used for several distinct clinical purposes, most notably as a nitrogen binding agent to help manage ammonium levels in the body. It is also a primary component in allergenic extracts used for immunotherapy to desensitize patients against plant-related allergies. Additionally, it has roles as a lymphocyte growth factor and a nitrate vasodilator, making it useful in specialized immune and cardiovascular contexts. Healthcare providers may also use topical preparations to assist in wound healing and reducing skin inflammation. It is important to use the specific formulation prescribed for your particular condition.
The most common side effects of Plantago Major involve the gastrointestinal system, such as bloating, gas, and mild stomach discomfort, especially when starting oral therapy. For those receiving the drug via injection for allergies, localized redness, itching, and swelling at the injection site are very frequent. Some patients may also notice a change in bowel habits due to the high mucilage content of the plant. Most of these effects are mild and tend to resolve as the body becomes accustomed to the medication. However, any persistent or worsening symptoms should be discussed with a healthcare provider.
It is generally advised to limit or avoid alcohol while taking Plantago Major. Alcohol can enhance the drug's nitrate-like vasodilatory effects, which may lead to an increased risk of dizziness, lightheadedness, or a sudden drop in blood pressure. Furthermore, alcohol can place additional stress on the liver, which is responsible for metabolizing the active components of the drug. Combining alcohol with nitrogen binding agents may also complicate the management of metabolic conditions. Always consult your doctor about your alcohol consumption habits before starting this medication.
Plantago Major is classified as Pregnancy Category C, meaning its safety has not been fully established through rigorous clinical trials in pregnant women. The primary concern, especially with the injectable allergenic extracts, is the risk of a systemic allergic reaction (anaphylaxis), which could severely reduce oxygen delivery to the fetus. While it is not known to be a direct teratogen, most healthcare providers recommend avoiding its use during pregnancy unless the medical necessity is absolute. If you are pregnant or planning to become pregnant, you must have a detailed discussion with your specialist regarding the risks and benefits. Maintenance of existing allergy shots may be continued under strict supervision, but starting new therapy is usually discouraged.
The time it takes for Plantago Major to work depends on the condition being treated. For nitrogen binding, the effect begins within 2 to 4 hours after an oral dose as the drug reaches the intestines. For wound healing, improvements in skin inflammation may be seen within a few days of starting topical treatment. However, for allergen immunotherapy, the process is much slower; it often takes 3 to 6 months of weekly injections to notice a reduction in allergy symptoms, and full benefits may not be realized for 12 months or more. Consistency in dosing is essential for achieving the desired therapeutic outcome.
You should not stop taking Plantago Major suddenly without first consulting your healthcare provider. If you are using it as a nitrogen binding agent for a metabolic condition, stopping abruptly could cause a dangerous spike in blood ammonia levels. In the case of allergy immunotherapy, stopping for an extended period and then restarting at the same dose can significantly increase your risk of a severe allergic reaction. If you need to discontinue the medication, your doctor will provide a safe tapering schedule or adjust your other treatments to ensure your condition remains stable.
If you miss an oral dose of Plantago Major, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule; never double the dose to make up for a missed one. If you miss an appointment for an allergenic extract injection, contact your allergist immediately. Depending on how much time has passed, they may need to reduce your next dose to ensure you do not have an adverse reaction. Keeping a consistent schedule is vital for the effectiveness of the treatment.
Weight gain is not a commonly reported side effect of Plantago Major. The drug does not contain significant calories, nor does it typically affect metabolic rate in a way that promotes fat storage. However, some patients may experience temporary bloating or water retention in the gut due to the mucilage content, which might be perceived as a slight change in weight. If you notice significant or rapid weight gain while taking this medication, it could be a sign of a different underlying issue, such as fluid retention related to kidney or heart function, and you should contact your doctor.
Plantago Major can interact with several other medications, so it is crucial to provide your doctor with a full list of everything you are taking. It should never be taken with PDE5 inhibitors like sildenafil due to the risk of severe low blood pressure. It can also interfere with the absorption of drugs like digoxin or affect the way beta-blockers and warfarin work in the body. Because it is a nitrogen binding agent, it may also interact with other metabolic treatments. Your healthcare provider will help you schedule your doses to minimize these interactions, often by separating the timing of different medications.
Plantago Major is available in various forms, including generic plant extracts and branded allergenic products. While the raw plant material is widely available, the clinical-grade, standardized extracts used for nitrogen binding or immunotherapy are specific pharmaceutical preparations. There are 56 linked drugs and brands that utilize these extracts. When filling a prescription, your pharmacist will provide the specific brand or generic version that your doctor has authorized. Always ensure you are using a standardized product from a reputable source to guarantee the correct concentration of active ingredients.
> Warning: Stop taking Plantago Major and call your doctor immediately if you experience any of these serious symptoms.
Prolonged use of Plantago Major as a nitrogen binding agent requires monitoring for nutritional deficiencies. Because the agent is non-selective in its binding, it may interfere with the absorption of certain fat-soluble vitamins (A, D, E, and K) and essential minerals over several months or years. Additionally, chronic stimulation of lymphocyte pathways requires periodic monitoring of complete blood counts (CBC) to ensure white blood cell levels remain within the normal range.
Allergenic extracts of Plantago Major are associated with a risk of severe systemic allergic reactions, including anaphylaxis, which can be fatal. These extracts should only be administered in a healthcare setting by personnel trained in the management of emergency allergic reactions. Patients must be observed for at least 30 minutes following administration. Patients with unstable asthma or those taking beta-blockers may be at increased risk for more severe reactions or may be less responsive to epinephrine treatment.
Report any unusual symptoms to your healthcare provider. Early detection of side effects is key to maintaining a safe and effective treatment plan.
To ensure safety while on Plantago Major therapy, your healthcare provider may order the following tests:
Plantago Major generally does not cause sedation or cognitive impairment. However, if you experience dizziness due to its vasodilatory effects or a systemic reaction following an injection, you should avoid driving or operating heavy machinery until you are certain the symptoms have passed.
Alcohol consumption should be limited while taking Plantago Major. Alcohol can exacerbate the vasodilatory effects of the drug, leading to an increased risk of hypotension. Furthermore, alcohol can stress the liver, potentially interfering with the metabolism of the drug's active components.
Do not stop taking Plantago Major suddenly without consulting your doctor, especially if you are using it for nitrogen regulation. Abrupt discontinuation can lead to a rapid rebound in ammonia levels, which can be dangerous. For immunotherapy, missing multiple doses may require you to restart the build-up phase at a lower concentration to avoid allergic reactions.
> Important: Discuss all your medical conditions, including any history of asthma, heart disease, or kidney problems, with your healthcare provider before starting Plantago Major.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication reconciliation is the only way to prevent dangerous interactions.
In these cases, a careful risk-benefit analysis by a healthcare provider is required:
Patients who are allergic to the following may also react to Plantago Major:
> Important: Your healthcare provider will evaluate your complete medical history, including any prior allergic reactions to plants or medications, before prescribing Plantago Major.
The safety of Plantago Major allergenic extracts has been established in children as young as 5 years old. However, its use as a nitrogen binding agent in the pediatric population is considered off-label and must be guided by specialized metabolic protocols. Growth parameters should be monitored in children on long-term therapy, as the drug’s interaction with lymphocyte growth factors could theoretically influence developmental pathways.
Clinical studies of Plantago Major have not included sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, the known decrease in renal and hepatic function in the elderly suggests that lower starting doses are appropriate. There is also an increased risk of constipation and fecal impaction in older adults taking mucilaginous agents; therefore, fiber and fluid intake must be strictly managed.
For patients with a GFR between 30-60 mL/min, a 25% dose reduction is typically advised. For those with a GFR < 30 mL/min (Stage 4 CKD), Plantago Major should be used only if essential, with daily monitoring of electrolytes. It is not significantly cleared by hemodialysis, so dosing should not be timed specifically around dialysis sessions, but the risk of fluid overload from the required water intake must be considered.
In patients with mild hepatic impairment, no adjustment is usually necessary for the nitrogen-binding effect. In moderate to severe cases (Child-Pugh B and C), the systemic immunomodulatory effects may be enhanced. Healthcare providers should monitor for signs of increased interferon-gamma activity, such as flu-like symptoms or persistent low-grade fever.
> Important: Special populations require individualized medical assessment. Always inform your specialist about pregnancy status or underlying organ dysfunction before beginning treatment.
| Parameter | Value |
|---|---|
| Bioavailability | 20-30% (for active glycosides) |
| Protein Binding | ~40% |
| Half-life | 4-6 hours (systemic metabolites) |
| Tmax | 1-2 hours (for absorbed components) |
| Metabolism | Hepatic (Phase I/II); Gut microbial hydrolysis |
| Excretion | Fecal (Major); Renal (~15-20%) |
Plantago Major is uniquely positioned across several therapeutic classes. While its primary EPC is a Nitrogen Binding Agent, it is pharmacologically related to other nitrogen scavengers like sodium phenylbutyrate. In the realm of immunology, it is grouped with other plant-derived allergenic extracts used for desensitization.